To better understand the role of dopamine D-4 receptor (D4R) in glioblastoma (GBM), in the present paper, new ligands endowed with high affinity and selectivity for D4R were discovered starting from the brain penetrant and D4R selective lead compound 1-(3-(4-phenylpiperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one (6). In particular, the D4R antagonist 24, showing the highest affinity and selectivity over D2R and D3R within the series (D-2/D-4 = 8318, D-3/D-4 = 3715), and the biased ligand 29, partially activating D4R G(i)-/G(o)-protein and blocking beta-arrestin recruitment, emerged as the most interesting compounds. These compounds, evaluated for their GBM antitumor activity, induced a decreased viability of GBM cell lines and primary GBM stem cells (GSC#83), with the maximal efficacy being reached at a concentration of 10 mu M. Interestingly, the treatment with both compounds 24 and 29 induced an increased effect in reducing the cell viability with respect to temozolomide, which is the first-choice chemotherapeutic drug in GBM.

Highly Potent and Selective Dopamine D4 Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma / P. Pavletić, A. Semeano, H. Yano, A. Bonifazi, G. Giorgioni, A. Piergentili, W. Quaglia, M.G. Sabbieti, D. Agas, G. Santoni, R. Pallini, L. Ricci-Vitiani, E. Sabato, G. Vistoli, F. Del Bello. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 65:18(2022 Sep 13), pp. 12124-12139. [10.1021/acs.jmedchem.2c00840]

Highly Potent and Selective Dopamine D4 Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma

E. Sabato;G. Vistoli;
2022

Abstract

To better understand the role of dopamine D-4 receptor (D4R) in glioblastoma (GBM), in the present paper, new ligands endowed with high affinity and selectivity for D4R were discovered starting from the brain penetrant and D4R selective lead compound 1-(3-(4-phenylpiperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one (6). In particular, the D4R antagonist 24, showing the highest affinity and selectivity over D2R and D3R within the series (D-2/D-4 = 8318, D-3/D-4 = 3715), and the biased ligand 29, partially activating D4R G(i)-/G(o)-protein and blocking beta-arrestin recruitment, emerged as the most interesting compounds. These compounds, evaluated for their GBM antitumor activity, induced a decreased viability of GBM cell lines and primary GBM stem cells (GSC#83), with the maximal efficacy being reached at a concentration of 10 mu M. Interestingly, the treatment with both compounds 24 and 29 induced an increased effect in reducing the cell viability with respect to temozolomide, which is the first-choice chemotherapeutic drug in GBM.
Humans; Ligands; Temozolomide; beta-Arrestins; Dopamine Antagonists; Glioblastoma; Receptors, Dopamine D4;
Settore CHIM/08 - Chimica Farmaceutica
Article (author)
File in questo prodotto:
File Dimensione Formato  
jm2c00840.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 5.64 MB
Formato Adobe PDF
5.64 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/939471
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact